Fu Hong Han Lin (02696) was included in the Hang Seng Composite Index and is expected to become the Hong Kong Stock Exchange Standard

Zhitongcaijing · 2d ago

Zhitong Finance App learned that on August 21, 2026, Hang Seng Index Company announced the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026, of which Fu Hong Han Lin (02696) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Fuhong Hanlin may be transferred to Hong Kong Stock Connect because it has met a range of standards including market value and liquidity.

Goldman Sachs recently released a research report stating that it maintains Fu Hong Hanlin's “buy” rating and raised its 12-month target price from HK$104.79 to HK$112.01. In the report, Goldman Sachs analyzed the strategic cooperation between Fuhong Hanlin and global generic drug and biosimilar company Sandoz, and believes that the transaction structure is significantly more attractive than the traditional licensing (license-out) model, marking a new stage where Fuhong Hanlin is moving from a single product overseas to a global biosimilar platform company.